Nautilus Biotechnology vs ConcertAI

Side-by-side comparison of AI visibility scores, market position, and capabilities

ConcertAI leads in AI visibility (74 vs 34)
Nautilus Biotechnology logo

Nautilus Biotechnology

EmergingBiotechnology

Single-Molecule Proteomics

Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previously impossible.

AI VisibilityBeta
Overall Score
D34
Category Rank
#175 of 198
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
30
Gemini
31

About

Nautilus Biotechnology is a proteomics company founded in 2016 and publicly listed on Nasdaq, developing a revolutionary platform for analyzing proteins at single-molecule resolution. While genomics has transformed medicine through DNA and RNA sequencing, the proteome is the actual functional layer of biology where drug targets, disease biomarkers, and therapeutic mechanisms operate. Nautilus is building a platform that can identify and quantify thousands of proteins simultaneously from tiny biological samples using a fluorescence-based single-molecule detection approach without requiring mass spectrometry. The platform promises to enable proteomics studies at a scale and depth comparable to what next-generation sequencing delivered to genomics, unlocking new insights into disease biology and drug development. Nautilus is in the instrument development phase and targets pharmaceutical research, clinical diagnostics, and academic biology. The company has raised over $250M and is building manufacturing capabilities for a planned commercial instrument launch that could define a new era in proteomics research.

Full profile
ConcertAI logo

ConcertAI

LeaderLife Sciences & BioTech

Oncology AI & Real-World Data

ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.

AI VisibilityBeta
Overall Score
B74
Category Rank
#2 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
69
Gemini
70

About

ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#175
Category Rank
#2
82
AI Consensus
80
stable
Trend
stable
36
ChatGPT
73
30
Perplexity
69
31
Gemini
70
28
Claude
70
31
Grok
77

Key Details

Category
Single-Molecule Proteomics
Oncology AI & Real-World Data
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Nautilus Biotechnology
Single-Molecule Proteomics

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.